Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers

Background: Multiple anti-PD-1/PD-L1 antibodies have been approved, and in some diseases, there is a choice of more than one. Comparative efficacy, safety and tolerability are unknown. Methods: Randomized trials (RCTs) supporting the registration of single agent anti-PD1 or anti-PDL1 inhibitors betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Showbaki, Laith, Nadler, Michelle B., Desnoyers, Alexandra, Almugbel, Fahad A., Cescon, David W., Amir, Eitan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176414/
https://www.ncbi.nlm.nih.gov/pubmed/34093837
http://dx.doi.org/10.7150/jca.57413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176414/
https://www.ncbi.nlm.nih.gov/pubmed/34093837
http://dx.doi.org/10.7150/jca.57413

Ejemplares similares